ChartRow logo
Share this page
ANAB
$46.61-4.31%
as of close, Oct 16, 2026
☾ AH $46.61 -4.31%
PeersMRNALLYMDTUNHJNJTMO

AnaptysBio Inc. trailing returns

How AnaptysBio Inc. (ANAB) has performed over the last day, week, month and year, over 5 years, and since inception, through October 16, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-16. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day-4.3%+0.0%-4.3%—
5 days+1.4%+0.0%+1.4%-4.3%Oct 16
1 month-14.2%+0.0%-14.2%-17.4%Oct 13
YTD+44.2%+0.0%+44.2%-34.7%Oct 13
1 year+103.2%+0.0%+103.2%-34.7%Oct 2026
5 years+19.5%+0.0%+19.5%+143.9%-69.3%Feb 2025
Since inception (2017)+15.7%+0.0%+15.7%+311.3%-92.1%Nov 2019

Growth of ANAB#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years+19.5%/year · +143.9%
  • Since inception (2017)+15.7%/year · +311.3%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-16). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in ANAB's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is AnaptysBio Inc.'s return since inception?
Since 2017, AnaptysBio Inc. (ANAB) has compounded at about +15.7% a year — +311.3% in total.

More on AnaptysBio Inc.